558 related articles for article (PubMed ID: 10937514)
1. Bromocriptine: a novel approach to the treatment of type 2 diabetes.
Pijl H; Ohashi S; Matsuda M; Miyazaki Y; Mahankali A; Kumar V; Pipek R; Iozzo P; Lancaster JL; Cincotta AH; DeFronzo RA
Diabetes Care; 2000 Aug; 23(8):1154-61. PubMed ID: 10937514
[TBL] [Abstract][Full Text] [Related]
2. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
[TBL] [Abstract][Full Text] [Related]
3. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
4. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes.
Kelley DE; Kuller LH; McKolanis TM; Harper P; Mancino J; Kalhan S
Diabetes Care; 2004 Jan; 27(1):33-40. PubMed ID: 14693963
[TBL] [Abstract][Full Text] [Related]
5. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects.
Cincotta AH; Meier AH
Diabetes Care; 1996 Jun; 19(6):667-70. PubMed ID: 8725871
[TBL] [Abstract][Full Text] [Related]
6. Does bromocriptine improve glycemic control of obese type-2 diabetics?
Aminorroaya A; Janghorbani M; Ramezani M; Haghighi S; Amini M
Horm Res; 2004; 62(2):55-9. PubMed ID: 15205563
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
Kelley DE; Bray GA; Pi-Sunyer FX; Klein S; Hill J; Miles J; Hollander P
Diabetes Care; 2002 Jun; 25(6):1033-41. PubMed ID: 12032111
[TBL] [Abstract][Full Text] [Related]
8. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
[TBL] [Abstract][Full Text] [Related]
9. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
10. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
Freemark M; Bursey D
Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
[TBL] [Abstract][Full Text] [Related]
11. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.
Fritsche A; Schmülling RM; Häring HU; Stumvoll M
Acta Diabetol; 2000 Mar; 37(1):13-8. PubMed ID: 10928231
[TBL] [Abstract][Full Text] [Related]
12. Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo.
Roger P; Auclair J; Drain P
J Diabetes Complications; 1999; 13(2):62-7. PubMed ID: 10432168
[TBL] [Abstract][Full Text] [Related]
13. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.
Herrmann BL; Berg C; Vogel E; Nowak T; Renzing-Koehler K; Mann K; Saller B
Horm Metab Res; 2004 Jan; 36(1):54-61. PubMed ID: 14983408
[TBL] [Abstract][Full Text] [Related]
14. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.
Vinik AI; Cincotta AH; Scranton RE; Bohannon N; Ezrokhi M; Gaziano JM
Endocr Pract; 2012; 18(6):931-43. PubMed ID: 23186965
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet.
Ludvik B; Neuffer B; Pacini G
Diabetes Care; 2004 Feb; 27(2):436-40. PubMed ID: 14747225
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
17. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
Miyazaki Y; Matsuda M; DeFronzo RA
Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
[TBL] [Abstract][Full Text] [Related]
18. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
Cusi K; Consoli A; DeFronzo RA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4059-67. PubMed ID: 8923861
[TBL] [Abstract][Full Text] [Related]
19. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Buse JB; Rubin CJ; Frederich R; Viraswami-Appanna K; Lin KC; Montoro R; Shockey G; Davidson JA
Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Luis Bautista J; Bugos C; Dirnberger G; Atherton T
Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
